Boston Scientific Corp (BSX) SEC filings

BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3051% below fair value

$44.34+0.14 (+0.32%)

Close on Nov 13, 2026Market cap $64.26BP/E 18.8Yield –

SEC filings

40 of Boston Scientific's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 2, 2026	SEC EDGAR
Current report	8-K	Oct 28, 2026	Oct 28, 2026	SEC EDGAR
Current report	8-K	Oct 1, 2026	Oct 7, 2026	SEC EDGAR
Current report	8-K	Sep 21, 2026	Sep 23, 2026	SEC EDGAR
Current report	8-K	Sep 7, 2026	Sep 8, 2026	SEC EDGAR
Current report	8-K	Aug 26, 2026	Aug 26, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 3, 2026	SEC EDGAR
Current report	8-K	Jul 29, 2026	Jul 29, 2026	SEC EDGAR
Current report	8-K	Jul 21, 2026	Jul 27, 2026	SEC EDGAR
Current report	8-K	May 18, 2026	May 18, 2026	SEC EDGAR
Current report	8-K	May 18, 2026	May 18, 2026	SEC EDGAR
Current report	8-K	Apr 30, 2026	May 5, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 1, 2026	SEC EDGAR
Current report	8-K	Apr 22, 2026	Apr 22, 2026	SEC EDGAR
Current report	8-K	Mar 28, 2026	Mar 30, 2026	SEC EDGAR
Proxy statement	DEF 14A	Mar 18, 2026	Mar 18, 2026	SEC EDGAR
Current report	8-K	Feb 26, 2026	Feb 26, 2026	SEC EDGAR
Current report	8-K	Feb 18, 2026	Feb 23, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 17, 2026	SEC EDGAR
Current report	8-K	Feb 2, 2026	Feb 5, 2026	SEC EDGAR
Current report	8-K	Feb 4, 2026	Feb 4, 2026	SEC EDGAR
Current report	8-K	Jan 14, 2026	Jan 15, 2026	SEC EDGAR
Current report	8-K	Jan 15, 2026	Jan 15, 2026	SEC EDGAR
Current report	8-K	Nov 18, 2025	Nov 19, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 3, 2025	SEC EDGAR
Current report	8-K	Oct 22, 2025	Oct 23, 2025	SEC EDGAR
Current report	8-K	Oct 22, 2025	Oct 22, 2025	SEC EDGAR
Current report	8-K	Aug 29, 2025	Sep 4, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 1, 2025	SEC EDGAR
Current report	8-K	Jul 23, 2025	Jul 23, 2025	SEC EDGAR
Current report	8-K	May 28, 2025	May 28, 2025	SEC EDGAR
Current report	8-K	May 1, 2025	May 6, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 1, 2025	SEC EDGAR
Current report	8-K	Apr 18, 2025	Apr 23, 2025	SEC EDGAR
Current report	8-K	Apr 23, 2025	Apr 23, 2025	SEC EDGAR
Proxy statement	DEF 14A	Mar 19, 2025	Mar 19, 2025	SEC EDGAR
Current report	8-K	Feb 21, 2025	Feb 26, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 18, 2025	SEC EDGAR
Current report	8-K	Feb 9, 2025	Feb 12, 2025	SEC EDGAR
Current report	8-K	Feb 5, 2025	Feb 5, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Boston Scientific's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Nov 6, 2003
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BSX.

Compare: BSX vs BDX · BSX vs BAX · BSX vs SYK · BSX vs MDLN · BSX vs SOLV

Revenue growth8.9% · median 6.6%

Gross margin69.1% · median 46.9%

Operating margin18.7% · median 5.7%

Company	Revenue	Growth
MDLN	$30.68B	–
SYK	$26.30B	+7.9%
BDX	$23.25B	+17.4%
BSX	$21.07B	+8.9%
BAX	$11.61B	+5.3%
SOLV	$8.16B	-2.8%

Company

Next earnings (est.): Feb 3, 2027, before open
Exchange: NYSE
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 59,000
Held by institutions: 92.1%
Auditor: Ernst & Young LLP
SEC CIK: 885725

Advertisement
300 × 250

See a number that looks wrong?